

Amniotic Products Market by Type (Cryopreserved Amniotic Membranes, Dehydrated Amniotic Membranes), Application (Wound Care, Ophthalmology, Orthopedics), End User (Hospital & Ambulatory Surgical Centers) - Global Forecast to 2028

<https://marketpublishers.com/r/A75D332D5A1BEN.html>

Date: July 2023

Pages: 175

Price: US\$ 4,950.00 (Single User License)

ID: A75D332D5A1BEN

Abstracts

The global Amniotic Products Market is projected to reach USD 1,289 Million by 2028 from USD 900 Million in 2023, at a CAGR of 7.4% during the forecast period. The growth of this market is majorly driven by Increasing number of ophthalmology, cosmetic, and orthopedic surgeries and Strategic Collaborations and Partnerships. However, Challenges associated with cost and affordability may threaten the growth of this market.

“Dehydrated Amniotic Membrane in the type of segment to witness the second highest growth during the forecast period.”

Based on the Type, the Amniotic products market is segmented into Cryopreserved Amniotic Membrane, and Dehydrated Amniotic Membrane. The Dehydrated Amniotic Membrane is projected to grow at the second highest CAGR during the forecast period. The significant factors contributing to the growth of this market is its application reliability for instance, Dehydrated amniotic membranes have logistical advantages over cryopreserved amniotic membranes as cryopreserved membranes require specialized storage and transport methods, Dehydrated amniotic membranes can be rehydrated before use, allowing for greater flexibility in their application, Reduced Risk of Disease Transmission as during the dehydration processes, such as freeze-drying, can help inactivate or eliminate potential pathogens present in the amniotic membrane.

“Asia Pacific is estimated to register the third highest CAGR during the forecast period.”

In this report, the amniotic products market is segmented into four major regional segments: North America, Europe, Asia Pacific, Latin America, Middle East & Africa. The market in Asia Pacific is projected to register the third highest growth rate during the forecast period. The growth in this market is primarily driven by the The growing awareness about the benefits of advanced wound care products, the rising geriatric population, increasing prevalence of chronic wounds, and growth in the number of people suffering from pressure ulcers, ophthalmic and orthopedic surgeries.

Breakdown of supply-side primary interviews, by company type, designation, and region:

By Company Type: Tier 1 (48%), Tier 2 (34%), and Tier 3 (18%)

By Designation: C-level (33%), Director-level (40%), and Others (27%)

By Region: North America (36%), Europe (28%), AsiaPacific (19%), Latin America (10%), Middle East & Africa (7%),

List of Companies Profiled in the Report

mimedx (US)

Smith+Nephew (UK)

Organogenesis Inc. (US)

Integra LifeSciences (US)

Stryker (US)

APPLIED BIOLOGICS. (US)

Celularity Inc. (US)

Corza Ophthalmology (US)

Lucina BioSciences (US)

Next Biosciences. (South Africa)

Skye Biologics Holdings, LLC (US)

BioTissue. (US)

Ventris Medical, LLC (US)

Stimlabs LLC (US)

VIVEX Biologics, Inc. (US)

LifeCell (India)

NuVision Biotherapies Ltd (UK)

Genesis Biologics, Inc. (US)

SURGILOGIX (US)

Tides Medical (US)

Orthofix US LLC. (US)

AlloSource (US)

Merakris Therapeutics, Inc. (US)

MTF Biologics (US)

Surgenex (US)

SURGITECH INNOVATION (India)

Research Coverage:

This report studies the amniotic products market based on product and region. The report also analyzes factors (such as drivers, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total Amniotic Products market. The report forecasts the revenue of the market segments with respect to five major regions.

Reasons to Buy the Report:

The report provides insights on the following pointers:

Market Penetration: Comprehensive information on Amniotic Products products offered by the top 26 players in the amniotic products market. The report analyzes the amniotic products market by Type, and region.

Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various securement devices across key geographic regions.

Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the amniotic products market.

Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the amniotic products market.

Contents

1 INTRODUCTION

1.1 STUDY OBJECTIVES

1.2 MARKET DEFINITION

1.2.1 INCLUSIONS AND EXCLUSIONS

1.3 MARKET SCOPE

FIGURE 1 AMNIOTIC PRODUCTS MARKET SEGMENTATION

1.3.1 REGIONS CONSIDERED

1.3.2 YEARS CONSIDERED

1.4 CURRENCY CONSIDERED

1.5 STAKEHOLDERS

1.6 LIMITATIONS

1.7 RECESSION IMPACT

1.8 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA

FIGURE 2 AMNIOTIC PRODUCTS MARKET: RESEARCH DESIGN

2.2 SECONDARY DATA

2.2.1 SECONDARY SOURCES

2.3 PRIMARY DATA

FIGURE 3 PRIMARY SOURCES

2.3.1 KEY DATA FROM PRIMARY SOURCES

2.3.2 KEY INDUSTRY INSIGHTS

FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION

2.4 MARKET SIZE ESTIMATION

FIGURE 5 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH

2.4.1 GROWTH FORECAST

FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS

FIGURE 7 TOP-DOWN APPROACH

2.5 MARKET BREAKDOWN AND DATA TRIANGULATION

FIGURE 8 DATA TRIANGULATION METHODOLOGY

2.6 MARKET SHARE ANALYSIS

2.7 RESEARCH ASSUMPTIONS

2.8 RESEARCH LIMITATIONS

2.9 RISK ASSESSMENT

2.10 GROWTH RATE ASSUMPTIONS

2.11 RECESSION IMPACT ANALYSIS

3 EXECUTIVE SUMMARY

FIGURE 9 AMNIOTIC PRODUCTS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)

FIGURE 10 AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)

FIGURE 11 AMNIOTIC PRODUCTS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)

FIGURE 12 AMNIOTIC PRODUCTS MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)

4 PREMIUM INSIGHTS

4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN AMNIOTIC PRODUCTS MARKET

FIGURE 13 GROWING TARGET PATIENT POPULATION TO DRIVE MARKET

4.2 AMNIOTIC PRODUCTS MARKET, BY TYPE

FIGURE 14 CRYOPRESERVED AMNIOTIC MEMBRANES SEGMENT TO REGISTER HIGHER CAGR DURING FORECAST PERIOD

4.3 NORTH AMERICA: AMNIOTIC PRODUCTS MARKET, BY TYPE AND COUNTRY

FIGURE 15 US ACCOUNTED FOR LARGEST MARKET SHARE IN NORTH AMERICA IN 2022

4.4 AMNIOTIC PRODUCTS MARKET, BY COUNTRY

FIGURE 16 US AND UK TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW

5.1 INTRODUCTION

FIGURE 17 AMNIOTIC PRODUCTS MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES

5.2 MARKET DYNAMICS

5.2.1 DRIVERS

5.2.1.1 Growth in target patient population

TABLE 1 GLOBAL PREVALENCE OF DIABETES

5.2.1.2 Rising incidence of burn injuries and increasing number of traumatic wounds

5.2.1.3 Wound care awareness programs and increasing funding for wound care treatment and management

TABLE 2 WOUND CARE AWARENESS INITIATIVES

TABLE 3 FUNDING FOR REGENERATIVE MEDICINE RESEARCH BY NIH UNDER 21ST CENTURY CURES ACT

TABLE 4 FUNDING INITIATIVES FROM CORPORATE PARTNERSHIPS IN 2022 (USD MILLION)

TABLE 5 FUNDING FROM CORPORATE PARTNERSHIPS IN 2021 (USD MILLION)

FIGURE 18 ARTICLES RELATED TO AMNIOTIC PRODUCTS PUBLISHED DURING 2010–2021

5.2.1.4 Increasing number of amniotic membrane transplantations

TABLE 6 NUMBER OF AMNIOTIC MEMBRANE TRANSPLANTATIONS PERFORMED IN UNIVERSITY EYE HOSPITAL T?BINGEN, GERMANY

5.2.1.5 Increasing number of ophthalmology, cosmetic, and orthopedic surgeries

5.2.1.6 Strategic collaborations and partnerships

5.2.1.7 Favorable reimbursement policies

TABLE 7 MEDICARE ALLOWABLE AMOUNTS (USD)

5.2.2 OPPORTUNITIES

5.2.2.1 Untapped opportunities in emerging economies

TABLE 8 STRATEGIC DEVELOPMENTS IN ASIA PACIFIC

5.2.2.2 Implementation of 21st Century Cures Act (US)

5.2.2.3 Increasing demand for stem cell research and regenerative medicine

FIGURE 19 STEM CELL RESEARCH FUNDING FROM 2011 TO 2020

TABLE 9 NIH FUNDING FOR CELL-BASED RESEARCH, 2016–2021 (USD MILLION)

5.2.3 CHALLENGES

5.2.3.1 Complications and limitations associated with use of amniotic membranes

5.2.3.2 Ethical and legal concerns of using amniotic membranes

5.2.3.3 High cost of amniotic membrane products

5.2.3.4 Competition from alternative therapies

5.2.4 TRENDS

5.2.4.1 Increasing clinical trials for stem cell and chimeric antigen receptor-T cell therapies

5.2.4.2 Expanding applications and rising focus on standardization and regulation of amniotic products

5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS

5.3.1 REVENUE SHIFT AND REVENUE POCKETS FOR AMNIOTIC PRODUCT MANUFACTURERS

5.3.2 REVENUE SHIFT IN AMNIOTIC PRODUCTS MARKET

5.4 PRICING ANALYSIS

TABLE 10 PRICES OF AMNIOTIC PRODUCTS

5.5 SUPPLY CHAIN ANALYSIS

FIGURE 20 DIRECT DISTRIBUTION: STRATEGY PREFERRED BY PROMINENT COMPANIES

5.6 VALUE CHAIN ANALYSIS

FIGURE 21 VALUE CHAIN ANALYSIS: MAJOR VALUE-ADDED DURING DEVELOPMENT PHASE

5.7 ECOSYSTEM ANALYSIS

5.7.1 ROLE IN ECOSYSTEM

TABLE 11 ROLE OF KEY PLAYERS IN ECOSYSTEM

FIGURE 22 KEY PLAYERS IN AMNIOTIC PRODUCTS ECOSYSTEM

5.8 TECHNOLOGY ANALYSIS

5.9 PATENT ANALYSIS

5.10 TRADE ANALYSIS

TABLE 12 IMPORT DATA FOR EXTRACTS OF GLANDS OR OTHER ORGANS OR OF THEIR SECRETIONS FOR ORGANO-THERAPEUTIC USE, BY COUNTRY, 2018–2022 (USD THOUSAND)

TABLE 13 EXPORT DATA FOR EXTRACTS OF GLANDS OR OTHER ORGANS OR OF THEIR SECRETIONS FOR ORGANO-THERAPEUTIC USE, BY COUNTRY, 2018–2022 (USD THOUSAND)

5.11 REGULATORY LANDSCAPE

5.11.1 NORTH AMERICA

5.11.2 EUROPE

5.11.3 EMERGING ECONOMIES

5.12 PORTER'S FIVE FORCES ANALYSIS

TABLE 14 AMNIOTIC PRODUCTS MARKET: IMPACT OF PORTER'S FIVE FORCES

5.12.1 INTENSITY OF COMPETITIVE RIVALRY

5.12.2 BARGAINING POWER OF SUPPLIERS

5.12.3 BARGAINING POWER OF BUYERS

5.12.4 THREAT OF SUBSTITUTES

5.12.5 THREAT OF NEW ENTRANTS

6 AMNIOTIC PRODUCTS MARKET, BY TYPE

6.1 INTRODUCTION

6.2 AMNIOTIC MEMBRANES

TABLE 15 AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)

6.2.1 CRYOPRESERVED AMNIOTIC MEMBRANES

6.2.1.1 Cryopreserved amniotic membranes to dominate amniotic membranes market during forecast period

TABLE 16 CRYOPRESERVED AMNIOTIC MEMBRANES MARKET, BY REGION, 2021–2028 (USD MILLION)

6.2.2 DEHYDRATED AMNIOTIC MEMBRANES

6.2.2.1 Logistical advantages of dehydrated amniotic membranes over cryopreserved amniotic membranes to drive demand

TABLE 17 DEHYDRATED AMNIOTIC MEMBRANES MARKET, BY REGION, 2021–2028 (USD MILLION)

7 AMNIOTIC PRODUCTS MARKET, BY APPLICATION

7.1 INTRODUCTION

7.2 PRIMARY NOTES

TABLE 18 AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

7.3 WOUND CARE

7.3.1 RISING INCIDENCE OF ULCERS, TRAUMATIC AND SURGICAL WOUNDS, AND BURNS TO DRIVE MARKET

TABLE 19 AMNIOTIC PRODUCTS MARKET FOR WOUND CARE, BY REGION, 2021–2028 (USD MILLION)

7.4 ORTHOPEDICS

7.4.1 BENEFITS OFFERED BY AMNIOTIC PRODUCTS FOR ORTHOPEDIC APPLICATIONS TO DRIVE MARKET

TABLE 20 AMNIOTIC PRODUCTS MARKET FOR ORTHOPEDICS, BY REGION, 2021–2028 (USD MILLION)

7.5 OPHTHALMOLOGY

7.5.1 LIGHTWEIGHT, THIN, AND ELASTIC NATURE OF AMNIOTIC MEMBRANES TO DRIVE DEMAND IN OPHTHALMOLOGY

TABLE 21 AMNIOTIC PRODUCTS MARKET FOR OPHTHALMOLOGY, BY REGION, 2021–2028 (USD MILLION)

7.6 OTHER APPLICATIONS

TABLE 22 ESTIMATED NUMBER OF COLORECTAL CANCER CASES AND DEATHS IN US IN 2020, BY AGE

TABLE 23 AMNIOTIC PRODUCTS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)

8 AMNIOTIC PRODUCTS MARKET, BY END USER

8.1 INTRODUCTION

TABLE 24 AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)

8.2 HOSPITALS & AMBULATORY SURGERY CENTERS

8.2.1 INCREASING NUMBER OF SURGICAL PROCEDURES TO DRIVE MARKET
TABLE 25 AMNIOTIC PRODUCTS MARKET FOR HOSPITALS & ASCS, BY REGION, 2021–2028 (USD MILLION)

8.3 OTHER END USERS

TABLE 26 AMNIOTIC PRODUCTS MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)

9 AMNIOTIC PRODUCTS MARKET, BY REGION

9.1 INTRODUCTION

TABLE 27 AMNIOTIC PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION)

9.2 NORTH AMERICA

FIGURE 23 NORTH AMERICA: AMNIOTIC PRODUCTS MARKET SNAPSHOT

TABLE 28 NORTH AMERICA: AMNIOTIC PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 29 NORTH AMERICA: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 30 NORTH AMERICA: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 31 NORTH AMERICA: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)

9.2.1 US

9.2.1.1 Growing geriatric population and high prevalence of chronic wounds and diabetes to drive market

TABLE 32 US: KEY MACRO INDICATORS

TABLE 33 US: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 34 US: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 35 US: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)

9.2.2 CANADA

9.2.2.1 Rising prevalence of target diseases to drive market
TABLE 36 INCIDENCE OF DIABETES IN CANADA, 2019 VS. 2029

TABLE 37 CANADA: KEY MACRO INDICATORS

TABLE 38 CANADA: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 39 CANADA: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 40 CANADA: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)

9.2.3 RECESSION IMPACT ON NORTH AMERICA

9.3 EUROPE

TABLE 41 EUROPE: HEALTHCARE EXPENDITURE, BY COUNTRY (% OF GDP)

TABLE 42 PREVALENCE OF DIABETES IN EUROPE, 2019 VS. 2045

TABLE 43 EUROPE: AMNIOTIC PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 44 EUROPE: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 45 EUROPE: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 46 EUROPE: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)

9.3.1 GERMANY

9.3.1.1 Increasing incidence of diabetes to drive market

TABLE 47 GERMANY: KEY MACRO INDICATORS

TABLE 48 GERMANY: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 49 GERMANY: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 50 GERMANY: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)

9.3.2 UK

9.3.2.1 High prevalence of diabetes activities to drive market

TABLE 51 UK: KEY MACRO INDICATORS

TABLE 52 UK: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 53 UK: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 54 UK: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)

9.3.3 FRANCE

9.3.3.1 Government support to drive demand for amniotic products

TABLE 55 FRANCE: KEY MACRO INDICATORS

TABLE 56 FRANCE: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 57 FRANCE: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 58 FRANCE: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)

9.3.4 REST OF EUROPE

TABLE 59 REST OF EUROPE: HEALTHCARE EXPENDITURE, BY COUNTRY, 2010 VS. 2021 (% OF GDP)

TABLE 60 REST OF EUROPE: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 61 REST OF EUROPE: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 62 REST OF EUROPE: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)

9.3.5 RECESSION IMPACT ON EUROPE

9.4 ASIA PACIFIC

FIGURE 24 ASIA PACIFIC: AMNIOTIC PRODUCTS MARKET SNAPSHOT

TABLE 63 ASIA PACIFIC: AMNIOTIC PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)

TABLE 64 ASIA PACIFIC: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 65 ASIA PACIFIC: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 66 ASIA PACIFIC: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)

9.4.1 CHINA

9.4.1.1 Increasing incidence of diabetes and growth in geriatric population to drive market

TABLE 67 CHINA: KEY MACRO INDICATORS

TABLE 68 CHINA: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 69 CHINA: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 70 CHINA: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)

9.4.2 JAPAN

9.4.2.1 Growing geriatric population to drive market

TABLE 71 JAPAN: KEY MACRO INDICATORS

TABLE 72 JAPAN: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 73 JAPAN: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 74 JAPAN: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)

9.4.3 REST OF ASIA PACIFIC

TABLE 75 REST OF ASIA PACIFIC: DIABETES PREVALENCE (% OF POPULATION AGED 20–79), BY COUNTRY, 2021

TABLE 76 REST OF ASIA PACIFIC: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 77 REST OF ASIA PACIFIC: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 78 REST OF ASIA PACIFIC: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)

9.4.4 RECESSION IMPACT ON ASIA PACIFIC

9.5 LATIN AMERICA

9.5.1 INCREASING PREVALENCE OF DIABETES TO DRIVE MARKET

TABLE 79 LATIN AMERICA: DIABETES PREVALENCE (% OF POPULATION AGED 20–79), BY COUNTRY, 2021

TABLE 80 LATIN AMERICA: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 81 LATIN AMERICA: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 82 LATIN AMERICA: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)

9.6 MIDDLE EAST & AFRICA

9.6.1 GROWTH IN HEALTHCARE INFRASTRUCTURE AND GOVERNMENT INITIATIVES TO DRIVE MARKET

TABLE 83 MIDDLE EAST & AFRICA: DIABETES PREVALENCE (% OF POPULATION AGED 20–79), BY COUNTRY, 2021

TABLE 84 MIDDLE EAST & AFRICA: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)

TABLE 85 MIDDLE EAST & AFRICA: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)

TABLE 86 MIDDLE EAST & AFRICA: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION)

10 COMPETITIVE LANDSCAPE

10.1 OVERVIEW

10.2 STRATEGIES ADOPTED BY KEY PLAYERS

TABLE 87 OVERVIEW OF STRATEGIES ADOPTED BY KEY AMNIOTIC PRODUCT MARKET PLAYERS

10.3 MARKET SHARE ANALYSIS, 2022

TABLE 88 AMNIOTIC PRODUCTS MARKET: DEGREE OF COMPETITION (2022)

10.4 REVENUE SHARE ANALYSIS, 2022

FIGURE 25 AMNIOTIC PRODUCTS MARKET: REVENUE ANALYSIS OF TOP FOUR MARKET PLAYERS, 2020–2022

10.5 COMPANY EVALUATION QUADRANT

10.5.1 STARS

10.5.2 EMERGING LEADERS

10.5.3 PERVASIVE PLAYERS

10.5.4 PARTICIPANTS

FIGURE 26 AMNIOTIC PRODUCTS MARKET: COMPANY EVALUATION MATRIX, 2022

10.6 SMALL AND MEDIUM-SIZED ENTERPRISE/STARTUP EVALUATION QUADRANT

10.6.1 PROGRESSIVE COMPANIES

10.6.2 STARTING BLOCKS

10.6.3 RESPONSIVE COMPANIES

10.6.4 DYNAMIC COMPANIES

FIGURE 27 AMNIOTIC PRODUCTS MARKET: SMALL AND MEDIUM-SIZED ENTERPRISE/ STARTUP EVALUATION MATRIX, 2022

10.7 COMPETITIVE BENCHMARKING

TABLE 89 AMNIOTIC PRODUCTS MARKET: DETAILED LIST OF KEY SMALL AND MEDIUM-SIZED ENTERPRISES/STARTUPS

10.8 COMPETITIVE SCENARIO

10.8.1 PRODUCT LAUNCHES

TABLE 90 PRODUCT LAUNCHES

10.8.2 DEALS

TABLE 91 DEALS

10.8.3 OTHERS

TABLE 92 OTHERS

10.9 COMPANY FOOTPRINT ANALYSIS

TABLE 93 COMPANY FOOTPRINT ANALYSIS

TABLE 94 COMPANY PRODUCT FOOTPRINT

TABLE 95 COMPANY REGIONAL FOOTPRINT

11 COMPANY PROFILES

(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*

11.1 KEY PLAYERS**11.1.1 MIMEDX GROUP, INC.**

TABLE 96 MIMEDX GROUP, INC.: COMPANY OVERVIEW

FIGURE 28 MIMEDX GROUP, INC.: COMPANY SNAPSHOT (2022)

11.1.2 SMITH+NEPHEW

TABLE 97 SMITH+NEPHEW: COMPANY OVERVIEW

FIGURE 29 SMITH+NEPHEW: COMPANY SNAPSHOT (2022)

11.1.3 ORGANOGENESIS INC.

TABLE 98 ORGANOGENESIS INC.: COMPANY OVERVIEW

FIGURE 30 ORGANOGENESIS INC.: COMPANY SNAPSHOT (2022)

11.1.4 INTEGRA LIFESCIENCES

TABLE 99 INTEGRA LIFESCIENCES: COMPANY OVERVIEW

FIGURE 31 INTEGRA LIFESCIENCES: COMPANY SNAPSHOT (2022)

11.1.5 STRYKER

TABLE 100 STRYKER: COMPANY OVERVIEW

FIGURE 32 STRYKER: COMPANY SNAPSHOT (2022)

11.1.6 APPLIED BIOLOGICS

TABLE 101 APPLIED BIOLOGICS: COMPANY OVERVIEW

11.1.7 CELULARITY INC.

TABLE 102 CELULARITY INC.: COMPANY OVERVIEW

11.1.8 CORZA OPHTHALMOLOGY

TABLE 103 CORZA OPHTHALMOLOGY: COMPANY OVERVIEW

11.1.9 LUCINA BIOSCIENCES

TABLE 104 LUCINA BIOSCIENCES: COMPANY OVERVIEW

11.1.10 NEXT BIOSCIENCES

TABLE 105 NEXT BIOSCIENCES: COMPANY OVERVIEW

11.1.11 SKYE BIOLOGICS HOLDINGS, LLC

TABLE 106 SKYE BIOLOGICS HOLDINGS, LLC: COMPANY OVERVIEW

11.1.12 SURGENEX

TABLE 107 SURGENEX: COMPANY OVERVIEW

11.2 OTHER PLAYERS**11.2.1 BIOTISSUE**

- 11.2.2 VENTRIS MEDICAL, LLC
- 11.2.3 STIMLABS LLC
- 11.2.4 VIVEX BIOLOGICS, INC.
- 11.2.5 LIFECELL
- 11.2.6 NUVISION BIOTHERAPIES LTD
- 11.2.7 GENESIS BIOLOGICS, INC.
- 11.2.8 SURGILOGIX
- 11.2.9 TIDES MEDICAL
- 11.2.10 ORTHOFIX US LLC
- 11.2.11 ALLOSOURCE
- 11.2.12 MERAKRIS THERAPEUTICS, INC.
- 11.2.13 MTF BIOLOGICS

Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats) might not be captured in case of unlisted companies.

12 APPENDIX

- 12.1 DISCUSSION GUIDE
- 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 12.3 CUSTOMIZATION OPTIONS
- 12.4 RELATED REPORTS
- 12.5 AUTHOR DETAILS

I would like to order

Product name: Amniotic Products Market by Type (Cryopreserved Amniotic Membranes, Dehydrated Amniotic Membranes), Application (Wound Care, Ophthalmology, Orthopedics), End User (Hospital & Ambulatory Surgical Centers) - Global Forecast to 2028

Product link: <https://marketpublishers.com/r/A75D332D5A1BEN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A75D332D5A1BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970